The trouble with having two primary endpoints on a clinical trial is it gives the drug two chances to fail. Annovis Bio, Inc. learned this lesson the hard way yesterday, after it admitted – eventually – that its mid-stage trial of buntanetap in Alzheimer’s had hit just one of its two main outcome measures, and even then only in a subset of patients.
Key Takeaways
- Buntanetap has failed on one primary endpoint in the Phase II part of Annovis’s Alzheimer’s trial, and barely scraped a questionable subgroup hit on the other
- A Phase III Parkinson’s trial should yield data in a couple of months, but last-minute changes to the study’s timeline and design raise
Shareholders ran for the hills, wiping 60% off the company’s share price on the NYSE. Annovis is now dependent on the readout of its Phase III trial of the same asset in Parkinson’s, which could come by mid-year